Health ❯ Healthcare ❯ Patient Care

Treatment Options

Innovative Therapies Oral Medications Combination Therapy Chemotherapy Subcutaneous Administration Personalized Medicine Cognitive Impairment Endocrine Therapy Hormone Therapy Cancer Treatment

3 ARTICLES

3d ago

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

An independent data monitoring committee concluded the study was unlikely to show sufficient efficacy, a result that will shape whether Sanofi advances other riliprubart trials.

8 ARTICLES

4d ago

AstraZeneca Advances Oral GLP‑1 Pill After Strong Phase II Results

4 ARTICLES

4d ago

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

4 ARTICLES

5d ago

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

5 ARTICLES

last wk.

Finerenone Slows Kidney Decline in Non‑Diabetic CKD, Trial Shows

7 ARTICLES

last wk.

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

12 ARTICLES

last wk.

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

8 ARTICLES

2w ago

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

3 ARTICLES

3w ago

FDA Approves Datroway as First‑Line Option for Immunotherapy‑Ineligible Triple‑Negative Breast Cancer

3 ARTICLES

3w ago

BioMarin Says Voxzogo Raised Growth Rates in Children With Hypochondroplasia

4 ARTICLES

3w ago

Apnimed Pill Cuts Sleep Apnea Events in Phase 3 as Company Seeks FDA Approval

3 ARTICLES

3w ago

Sanofi’s Efdoralprin Alfa Beats Standard Therapy in Phase 2 AATD Trial

5 ARTICLES

4w ago

Meta-Analysis Backs Low-Dose Digitalis for Heart Failure With Fewer Worsening Events

4 ARTICLES

last mo.

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

5 ARTICLES

last mo.

AI Flags Pancreatic Cancer on CT Scans Years Before Diagnosis, Study Says

8 ARTICLES

last mo.

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

Treatment Options

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

AstraZeneca Advances Oral GLP‑1 Pill After Strong Phase II Results

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

CagriSema Combo Lowers Blood Sugar and Drives Bigger Weight Loss Than Semaglutide Alone

Finerenone Slows Kidney Decline in Non‑Diabetic CKD, Trial Shows

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

Gene Test Lets Many Over-40 Breast Cancer Patients Skip Chemotherapy

Mezigdomide Triplet Cuts Risk of Myeloma Progression by 52% in Phase 3 Trial

FDA Approves Decnupaz for Rare Blood Cancer

Never miss stories about

Treatment Options

FDA Extends Review of AstraZeneca’s Camizestrant

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

FDA Approves Datroway as First‑Line Option for Immunotherapy‑Ineligible Triple‑Negative Breast Cancer

BioMarin Says Voxzogo Raised Growth Rates in Children With Hypochondroplasia

Apnimed Pill Cuts Sleep Apnea Events in Phase 3 as Company Seeks FDA Approval

Sanofi’s Efdoralprin Alfa Beats Standard Therapy in Phase 2 AATD Trial

Meta-Analysis Backs Low-Dose Digitalis for Heart Failure With Fewer Worsening Events

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

AI Flags Pancreatic Cancer on CT Scans Years Before Diagnosis, Study Says

FDA Approves Auvelity as First Non‑Antipsychotic for Alzheimer’s Agitation

Never miss stories about

Treatment Options